Lilly’s investigational Alzheimer’s to be investigated in prevention trial
The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
The Economist9h
Have doctors been wrong about how to treat Alzheimer’s disease?
Alzheimer’s disease affects more than 30m people worldwide, mostly the elderly. After the age of 65, the chance of developing ...
Clinical trials site shows Cassava Sciences REFOCUS-ALZ trial terminated
Cassava Sciences (SAVA)’ trial for simufilam 50 mg or 100 mg for mild-to-moderate Alzheimer’s disease, named “REFOCUS-ALZ,” has been ...
STAT20h
What happens when a rare disease drug seems to work, but the health care system doesn’t?
Cristina Brennan can hear the clock ticking. At the end of the year, her 12-year-old son Tristan will no longer have free ...
Annovis Bio begins pivotal phase 3 Alzheimer's drug trial
MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company trading near its 52-week low of $2.99, has announced the initiation of a Phase 3 trial for its Alzheimer's disease ...